Guidelines for Preparing Stability Protocols as per ICH Q1A(R2)
1) Purpose
The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for preparing a stability protocol for drug substances and drug products in compliance with the ICH Q1A(R2) guidelines. This SOP ensures that the stability protocol is comprehensive, clear, and in line with regulatory requirements.
2) Scope
This SOP applies to all personnel involved in the preparation and review of stability protocols for drug substances and drug products intended for global markets.
3) Responsibilities
Stability Testing Team: Responsible for drafting
Guidelines for Preparing Stability Data for US FDA Submissions
1) Purpose
The purpose of this Standard Operating Procedure (SOP) is to provide guidance on compiling and preparing stability data for submissions to the United States Food and Drug Administration (US FDA). This
2) Scope
This SOP applies to all personnel involved in the preparation, compilation, and submission of stability data for drug substances and drug products intended for the US market.
3) Responsibilities
Stability Testing Team: Responsible for generating
Quality Assurance (QA) Team: Responsible for reviewing stability data for completeness and compliance with regulatory guidelines.
Regulatory Affairs Team: Responsible for preparing and submitting the stability data package to the US FDA.
4) Procedure
4.1 Data Collection and Review
4.1.1 Collect all stability data generated from long-term, accelerated, and intermediate studies, as applicable.
4.1.2 Review the data for accuracy, completeness, and any out-of-specification (OOS) results or trends.
4.2 Formatting and Organization of Data
4.2.1 Organize the stability data into the required sections for submission to the US FDA, which typically includes:
- Summary of stability study design (e.g., type of study, storage conditions, and time points).
- Tabulated data presentation showing test results at each time point and storage condition.
- Graphical representations (e.g., plots of assay results, degradation product trends, etc.).
- Discussion of results, including any trends, deviations, or OOS results, and investigations conducted.
- Conclusion regarding the product’s shelf life, storage conditions, and any necessary labeling information.
4.3 Quality Assurance Review
4.3.1 Submit the compiled stability data package to the QA Team for review.
4.3.2 Address any discrepancies or omissions identified by the QA Team and revise the data package accordingly.
4.4 Submission Preparation
4.4.1 Prepare the electronic submission of the stability data package in the eCTD format as per US FDA requirements.
4.4.2 Ensure all documents are correctly formatted and compliant with US FDA standards.
4.4.3 Submit the stability data package electronically through the US FDA’s Electronic Submissions Gateway (ESG).
5) Abbreviations, if any
US FDA: United States Food and Drug Administration
OOS: Out-of-Specification
eCTD: Electronic Common Technical Document
ESG: Electronic Submissions Gateway
QA: Quality Assurance
6) Documents, if any
Stability data sheets, stability testing records, compiled stability data package, electronic submission records.
7) Reference, if any
US FDA Guidance for Industry: Stability Testing of Drug Substances and Drug Products, CFR Title 21.
8) SOP Version
Version 1.0